-
Mashup Score: 0
The treatment combination was found to reduce the risk of follicular lymphoma progression or death by 57%, a study has shown.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
The treatment combination was found to reduce the risk of follicular lymphoma progression or death by 57%, a study has shown.
Monjuvi/Revlimid/ Rituxan resulted in a 57% reduction in the risk of disease progression or death vs placebo/Revlimid/Rituxan in relapsed/refractory follicular #lymphoma. @ASH_hematology #ASH24 #hematology Listen to Dr. Poh break down the data here: https://t.co/ReoDq59PT8